Emergence of Psychedelic-assisted Psychotherapy (PAP) / Rising Approval for Additional Psychedelic Drugs / Growing Popularity of Psilocybin

DUBLIN, March 25, 2022 / PRNewswire / – The “Global Psychedelic Drugs Market: Analysis By Indication (ADHD, MDD, Bipolar, Migraine, Anxiety, Parkinson’s Disease, OUD, Alzheimer’s Disease, AUD, TUD, Eating Disorder, and Narcolepsy) Size & Trends with Impact of Covid-19 and Forecast up to 2025 “report has been added to ResearchAndMarkets.com’s offering.

Research and Markets Logo

The report provides an in depth analysis of the global psychedelic drugs market by value, by indication, etc. The report also provides a detailed analysis of the COVID-19 impact on the psychedelic drugs market.

Psychedelic drugs are a group of substances that are able to induce and enhance sensory perceptions, thoughts, and energy levels. Psychedelic drugs were used excessively in the 1960s, but the use was halted for mainly political reasons. However, recently, the use of psychedelics is evolving for the treatment of a variety of mental illnesses, including anxiety, depression, post-traumatic stress disorder, etc.

Some psychedelic drugs are extracted from plants or mushrooms, and some are synthetic (human-made). These drugs are now considered effective for patients with treatment-resistant depression, as they are fast-acting and long-lasting.

The most common psychedelic substances include: Ketamine, Psilocybin, Ibogaine, LSD, Dimethyltryptamine (DMT), or MDMA. The majority of psychedelic drugs under development are targeting mental and / or behavioral health indications. This is an area with significant unmet need.

The psychedelic drugs market can be segmented on the basis of indication (ADHD, MDD, Bipolar, Migraine, Anxiety, Parkinson’s Disease, OUD, Alzheimer’s Disease, AUD, TUD, Eating Disorder, and Narcolepsy); and drug type (Lysergic Acid Diethylamide (LSD), Ketamine, Psilocybin, 3,4-MethylEnedioxyMethamphetamine (MDMA), Ibogaine, and Others).

The global psychedelic drugs market has increased significantly during the past years and projections are made that the market would rise in the coming years. The psychedelic drugs market is expected to increase due to rising prevalence of depression and mental disorders, regulatory reforms, developments relating to psychedelics, changing perceptions, little severe side effects and cost effective, etc. Yet the market faces some challenges such as uncertainty around getting the FDA approval, early stage in lifecycle of the psychedelics industry, stigma associated with psychedelic drug use, etc.

The report also assesses the key opportunities in the market and outlines the factors that are and will be driving the growth of the industry. Growth of the overall global psychedelic drugs market has also been forecasted till the period 2025, taking into consideration the previous growth patterns, the growth drivers and the current and future trends.

The global psychedelic drugs market remains at an early stage in its life cycle, with most companies currently developing their go-to-market strategy. The market players of psychedelics are involved in the clinical trials of several psychedelic drugs to address mental health, which continues to present significant unmet need.

The key players of the psychedelic drugs market are COMPASS Pathways Plc, Mind Medicine (MindMed) Inc., Numinus Wellness Inc., and Johnson & Johnson are also profiled with their financial information and respective business strategies.

Key Topics Covered:

1. Executive Summary

2. Introduction
2.1 Psychedelic Drugs: An Overview
2.1.1 History of Psychedelic Drugs
2.1.2 Pros and Cons of Psychedelic Drugs
2.1.3 Major Types of Psychedelic Drugs
2.1.4 Potential Treatment Indications for Psychedelic Molecules
2.1.5 Psychedelic Classification
2.2 Psychedelic Drugs Segmentation: An Overview
2.2.1 Psychedelic Drugs Segmentation by Indication
2.2.2 Psychedelic Drugs Segmentation by Drug Type

3. Global Market Analysis
3.1 Global Psychedelic Drugs Market: An Analysis
3.1.1 Global Psychedelic Drugs Market by Value
3.1.2 Global Psychedelic Drugs Market by Indication (ADHD, MDD, Bipolar, Migraine, Anxiety, Parkinson’s Disease, OUD, Alzheimer’s Disease, AUD, TUD, Eating Disorder and Narcolepsy)
3.2 Global Psychedelic Drugs Market: Indication Analysis
3.2.1 Global Attention Deficit Hyperactivity Disorder (ADHD) Psychedelic Drugs Market by Value
3.2.2 Global Major Depressive Disorder (MDD) Psychedelic Drugs Market by Value
3.2.3 Global Bipolar Disorder Psychedelic Drugs Market by Value
3.2.4 Global Migraine Psychedelic Drugs Market by Value
3.2.5 Global Anxiety Psychedelic Drugs Market by Value
3.2.6 Global Parkinson’s Disease Psychedelic Drugs Market by Value
3.2.7 Global Opioid Use Disorder (OUD) Psychedelic Drugs Market by Value
3.2.8 Global Alzheimer’s Disease Psychedelic Drugs Market by Value
3.2.9 Global Alcohol Use Disorder (AUD) Psychedelic Drugs Market by Value
3.2.10 Global Tobacco Use Disorder (TUD) Psychedelic Drugs Market by Value
3.2.11 Global Eating Disorder Psychedelic Drugs Market by Value
3.2.12 Global Narcolepsy Psychedelic Drugs Market by Value

4. Impact of COVID-19
4.1 Impact of COVID-19
4.1.1 Impact of COVID-19 on Healthcare Sector
4.1.2 Impact of COVID-19 on Psychedelic Drugs Industry

5. Market Dynamics
5.1 Growth Driver
5.1.1 Rising Prevalence of Depression and Mental Disorders
5.1.2 Regulatory Reforms
5.1.3 Developments Relating to Psychedelics
5.1.4 Changing Perceptions
5.1.5 Little Severe Side Effects and Cost Effective
5.2 Challenges
5.2.1 Uncertainty around Getting the FDA Approval
5.2.2 Early Stage in Lifecycle of the Psychedelics Industry
5.2.3 Stigma Associated with Psychedelic Drugs Use
5.3 Market Trends
5.3.1 Rising Approval for Additional Psychedelic Drugs
5.3.2 Growing Popularity of Psilocybin
5.3.3 Rising Number of Potential Candidates for Breakthrough Therapy Designation (BTD)
5.3.4 Surging popularity of Micro-dosing in Psychedelics
5.3.5 Emergence of Psychedelic-assisted Psychotherapy (PAP)
5.3.6 Increasing Potential Treatment Indications for Psychedelic Drugs

6. Competitive Landscape
6.1 Global Psychedelic Drugs Market Players by Drug TAM
6.2 Global Psychedelic Drugs Market Players by Psychedelic Related Businesses
6.3 Global Psychedelic Drugs Market Players by Psychedelic-related Clinical Trials
6.4 Global Psychedelic Drugs Market Players by Breakthrough Therapy Designations (BTD) for Psychedelic Substances

7. Company Profiles
7.1 Business Overview
7.2 Business Strategy

For more information about this report visit https://www.researchandmarkets.com/r/qde2z5

Media Contact:

Research and Markets
Laura WoodSenior Manager
press@researchandmarkets.com

For EST Office Hours Call + 1-917-300-0470
For US / CAN Toll Free Call + 1-800-526-8630
For GMT Office Hours Call + 353-1-416-8900

US Fax: 646-607-1907
Fax (outside US): + 353-1-481-1716

Cision

Cision

View original content: https: //www.prnewswire.com/news-releases/global-psychedelic-drugs-markets-2022-2025-emergence-of-psychedelic-assisted-psychotherapy-pap–rising-approval-for-additional -psychedelic-drugs-growing-popularity-of-psilocybin-301510800.html

SOURCE Research and Markets

Leave a Comment